What is the most recent earnings date for BIO stock?
BIO-RAD LABORATORIES-A (BIO) last reported earnings on 2/12/2026.
BIO-RAD LABORATORIES-A (BIO) Earnings History & Surprises
NYSE:BIO • US0905722072
Current stock price
262.8 USD
+0.98 (+0.37%)
At close:
262.8 USD
0 (0%)
After Hours:
BIO Earnings overview
Past quarterly earnings results for BIO-RAD LABORATORIES-A (BIO), including EPS and revenue actuals, analyst estimates, and surprise percentages. This page focuses on historical performance (not forecasts).
Earnings Snapshot
Next Earnings Date
Upcoming- Release Date
- Apr 29, 2026
- Period
- Q1 / 2026
- EPS Estimate
- $2.00
- Revenue Estimate
- 591.52M
Last Reported
Most Recent- Release Date
- Feb 12, 2026
- Period
- Q4 / 2025
- EPS Reported
- $2.51
- EPS Surprise
- -7.97%
- Revenue Surprise
- -0.35%
Beat Rate
Last 8 Quarters 63%
EPS and Revenue beats vs estimates
Quarterly Earnings Historical Results
EPS & Revenue History (in USD): Actual vs estimated values, surprises, q2q growth and acceleration numbers quarterly history.
| Quarter | EPS | EPS Est | EPS Surprise | EPS Q2Q | Revenue | Revenue Est | Revenue Surprise | Revenue Q2Q |
|---|---|---|---|---|---|---|---|---|
| Q4 2025 | 2.51 | 2.73 | -7.97% | -13.45% | 693.2M | 695.65M | -0.35% | 3.85% |
| Q3 2025 | 2.26 | 1.95 | 15.74% | 12.44% | 653M | 657.81M | -0.73% | 0.50% |
| Q2 2025 | 2.61 | 1.75 | 49.07% | -16.08% | 651.6M | 621.36M | 4.87% | 2.06% |
| Q1 2025 | 2.54 | 1.83 | 38.97% | 10.92% | 585.4M | 579M | 1.11% | -4.16% |
| Q4 2024 | 2.90 | 2.90 | 0.10% | -6.45% | 667.5M | 686.09M | -2.71% | -2.01% |
| Q3 2024 | 2.01 | 1.17 | 72.05% | -13.73% | 649.729M | 634.46M | 2.41% | 2.79% |
| Q2 2024 | 3.11 | 2.03 | 52.84% | 3.67% | 638.476M | 652.25M | -2.11% | -6.26% |
| Q1 2024 | 2.29 | 2.17 | 5.67% | -31.44% | 610.82M | 625.28M | -2.31% | -9.75% |
| Q4 2023 | 3.10 | 2.85 | 8.96% | -6.34% | 681.184M | 691.94M | -1.55% | -6.73% |
| Q3 2023 | 2.33 | 2.81 | -17.09% | -10.38% | 632.1M | 696.46M | -9.24% | -7.15% |
| Q2 2023 | 3.00 | 2.71 | 10.88% | -11.24% | 681.11M | 704.94M | -3.38% | -1.45% |
| Q1 2023 | 3.34 | 3.58 | -6.64% | -32.39% | 676.844M | 696.73M | -2.85% | -3.32% |
| Q4 2022 | 3.31 | 3.48 | -4.96% | 3.12% | 730.3M | 749.67M | -2.58% | -0.34% |
| Q3 2022 | 2.60 | 2.81 | -7.47% | -29.92% | 680.8M | 686.74M | -0.86% | -8.86% |
| Q2 2022 | 3.38 | 2.83 | 19.58% | -4.52% | 691.1M | 689.45M | 0.24% | -3.46% |
| Q1 2022 | 4.94 | 3.44 | 43.76% | -5.18% | 700.1M | 681.85M | 2.68% | -3.67% |
| Q4 2021 | 3.21 | 2.88 | 11.49% | -19.95% | 732.8M | 739.3M | -0.88% | -7.22% |
| Q3 2021 | 3.71 | 2.46 | 50.71% | 23.67% | 747M | 668.49M | 11.74% | 15.40% |
| Q2 2021 | 3.54 | 2.69 | 31.54% | 119.88% | 715.9M | 638.1M | 12.19% | 33.34% |
| Q1 2021 | 5.21 | 3.03 | 72.12% | 172.77% | 726.8M | 667.59M | 8.87% | 27.15% |
| Q4 2020 | 4.01 | 3.33 | 20.49% | - | 789.8M | 693.67M | 13.86% | - |
| Q3 2020 | 3.00 | 1.82 | 64.86% | - | 647.3M | 576.28M | 12.32% | - |
| Q2 2020 | 1.61 | 1.24 | 30.31% | - | 536.9M | 522.22M | 2.81% | - |
| Q1 2020 | 1.91 | 1.58 | 20.84% | - | 571.6M | 552.32M | 3.49% | - |
Notes
- EPS and Revenue values are non-GAAP when available, otherwise GAAP.
- Surprise % is (Actual - Estimate) / |Estimate|. Green indicates positive surprise, red negative.
- Q2Q % is quarter-over-quarter growth. Green indicates growth, red indicates decline.
- Green right border indicates acceleration for sales or earnings growth. Acceleration is the case when the current Q2Q is above the previous Q2Q.
Earnings Q2Q Performance Trends
EPS Historical Q2Q growth and Acceleration
Revenue Historical Q2Q growth and Acceleration
Surprise distribution (Last 4 Quarters)
EPS beat statistics
EPS beat (4)
3
Average EPS beat (4)
23.95%
Max EPS beat (4)
49.07%
Min EPS beat (4)
-7.97%
Revenue beat statistics
Revenue beat (4)
2
Average Revenue beat (4)
1.22%
Max Revenue beat (4)
4.87%
Min Revenue beat (4)
-0.73%
Analysis
In the last 4 quarters, BIO has beaten EPS estimates in 3 out of 4 releases
BIO has beaten revenue estimates in 2 out of the last 4 releases
In the last 4 quarters, BIO has beaten the EPS estimates by 24.0% on average.
In the last 4 quarters, BIO has beaten the revenue estimates by 1.2% on average.
Related analysis
BIO-RAD LABORATORIES-A / BIO Earnings FAQ
Can you provide information on whether BIO-RAD LABORATORIES-A beat earnings estimates in the last quarter?
BIO-RAD LABORATORIES-A (BIO) missed EPS estimates and missed revenue estimates in the most recent quarter.
What percentage of the time does BIO stock beat earnings estimates?
In the last 4 quarters, BIO-RAD LABORATORIES-A (BIO) has beaten EPS estimates in 3 out of 4 releases.